Structural studies have revealed that the DNA-binding domain of p53 is necessary for these interactions, indicating that tumor-derived p53 mutants with impaired DNA-binding capacity may also fail to interact with Bcl-2 effectively [76]. The gene discussed is BCL2; the disease is neoplasm.